Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 1;148(12):1111-1119.
doi: 10.1001/jamaoto.2022.3269.

Quantifying Total and Out-of-Pocket Costs Associated With Head and Neck Cancer Survivorship

Sean T Massa  1 , Smrithi Chidambaram  1   2 , Peter Luong  1 , Evan M Graboyes  3   4 , Angela L Mazul  2   5
Affiliations

Quantifying Total and Out-of-Pocket Costs Associated With Head and Neck Cancer Survivorship

Sean T Massa et al. JAMA Otolaryngol Head Neck Surg. .

Abstract

Importance: Oncologic treatment is costly to the health care system and to individuals, but patients with head and neck cancer (HNC) also have long-term care needs after treatment. Survivors of HNC require specific consideration given their rapidly growing numbers. This subpopulation of cancer survivors often experiences long-term treatment-associated morbidity.

Objective: To describe the total and out-of-pocket (OOP) costs associated with HNC survivorship and the risk factors for financial toxicity among this population.

Design, setting, and participants: This was a retrospective review and economic evaluation of a cohort of US adults with a diagnosis of HNC from 2006 to 2018. The study used data the from IBM MarketScan Commercial Claims Database. Data were analyzed from November 2020 to June 2022.

Exposures: Treatment for HNC.

Main outcomes and measures: Total and OOP medical costs were assessed monthly and reported relative to the date of HNC diagnosis. The primary outcome was the difference between a patient's mean monthly survivorship costs (13-60 months after diagnosis) and mean monthly baseline costs (7-12 months before diagnosis). Univariate and multivariable linear regression models were created for total and OOP costs to generate coefficient estimates with 95% CIs.

Results: The study cohort of this economic evaluation included 19 098 patients with HNC (median [range] age, 56 [18-64] years; 14 144 [74.1%] men and 4954 [25.9%] women; race and ethnicity were not considered). Throughout the survivorship period, median total and OOP costs were $372 per month and $31 per month higher than baseline costs, respectively, with variation in expenses by demographic information, health plan type, and oncologic variables. In the multivariable model, greater total and OOP excess survivorship costs were associated with female sex ($343/mo; 95% CI, $126 to $560 and $9/mo; 95% CI, $4 to $14). Highest and lowest total excess survivorship costs associated with cancer site were seen for hypopharyngeal ($1908/mo; 95% CI, $1102 to $2714) and oropharyngeal cancers (-$703/mo; 95% CI, -$967 to -$439) vs oral cavity cancers. Compared with surgery or radiation therapy alone, multimodal treatment was generally associated with excess OOP survivorship costs.

Conclusions and relevance: The findings of this retrospective economic evaluation review suggest that the costs of HNC survivorship remain persistently elevated above baseline costs for at least 5 years after diagnosis. High survivorship costs were associated with female sex, hypopharyngeal tumors, and treatment with multimodal therapy. Practitioners should seek to minimize costs for these patients at higher-risk of financial toxicity after treatment and work to provide directed supportive services.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Graboyes reported grants from the US National Cancer Institute and the American College of Surgeons/Triological Society, and personal fees from Castle Biosciences, outside the submitted work; and serving as an editorial board member of JAMA Otolaryngology–Head & Neck Surgery. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Cohort Selection Diagram
Figure 2.
Figure 2.. Median Monthly Head and Neck Cancer Treatment Expenses Over Time
Figure 3.
Figure 3.. Median Monthly Head and Neck Cancer Treatment Expenses by Treatment Type
See this image and copyright information in PMC

Comment in

References

    1. Cohen EE, LaMonte SJ, Erb NL, et al. American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016;66(3):203-239. doi: 10.3322/caac.21343 - DOI - PubMed
    1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301. doi: 10.1200/JCO.2011.36.4596 - DOI - PMC - PubMed
    1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35. doi: 10.1056/NEJMoa0912217 - DOI - PMC - PubMed
    1. Song JS, Vallance P, Biron V, Jeffery CC. Epidemiological trends of head and neck cancer survivors in Alberta: towards improved understanding of the burden of disease. J Otolaryngol Head Neck Surg. 2020;49(1):46. doi: 10.1186/s40463-020-00443-4 - DOI - PMC - PubMed
    1. Cohen N, Fedewa S, Chen AY. Epidemiology and demographics of the head and neck cancer population. Oral Maxillofac Surg Clin North Am. 2018;30(4):381-395. doi: 10.1016/j.coms.2018.06.001 - DOI - PubMed

Publication types